Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
2017 · The Lancet · 883 citations
https://doi.org/10.1016/s0140-6736(17)32641-7
X
Xavier Hébuterne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
390
Papers
10.1K
Citations
56
h-index
109
i10-index
Xavier Hébuterne is an academic researcher from Centre Hospitalier Universitaire de Nice. The author has contributed to research in topics: Inflammatory Bowel Disease & Nutrition and Health in Aging & Microscopic Colitis. The author has an h-index of 56, co-authored 332 publications.
ORCID: 0000-0002-5903-8834Papers by this author
worksUpadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2022 · The Lancet · 544 citations
https://doi.org/10.1016/s0140-6736(22)00581-5
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
2017 · The Lancet · 197 citations
https://doi.org/10.1016/s0140-6736(17)30930-3
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
2017 · Gut · 107 citations
https://doi.org/10.1136/gutjnl-2016-313457
Risankizumab for Ulcerative Colitis
2024 · JAMA · 98 citations
https://doi.org/10.1001/jama.2024.12414
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · The Lancet · 67 citations
https://doi.org/10.1016/s0140-6736(24)01927-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat